Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,dividendsPaid,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,changeToInventory,changeToAccountReceivables,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,trailingAnnualDividendRate,trailingPE,trailingAnnualDividendYield,epsTrailingTwelveMonths,epsForward,currency,priceHint,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,exchange,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,market,marketState,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,ESALY,440038000000.0,286665984,41815000000,,55782000000,24802000000,42161000000,74725000000,159644000000,55407000000,55407000000,-12303000000,-374000000,,,,13477000000,198894000000,143487000000,39250000000,375000000,,42305000000,42161000000,110889000000.0,77619000000.0,381987000000.0,722552000000.0,154388000000.0,1129341000000.0,44986000000.0,22746000000.0,526030000000.0,54140000000.0,171625000000.0,73917000000.0,84778000000.0,213082000000.0,277934000000.0,65506000000.0,42770000000.0,107930000000.0,159074000000.0,562508000000.0,40467000000.0,492000000.0,236336000000.0,49913000000.0,89852000000.0,80776000000.0,1752000000.0,0.0,124000000.0,250000000.0,-22533000000.0,-63316000000.0,-35658000000.0,1021000000.0,-14271000000.0,9455000000.0,-40000000.0,-22938000000.0,155000000.0,-2571000000.0,-12118000000.0,,,284574000000.0,en-US,US,EQUITY,False,Delayed Quote,1.5378985,83.738 - 84.13,82.58,0.0,0.0,0,0,finmb_685500,Other OTC,"Eisai Co., Ltd.",JPY,70543,9750,21.899998,0.35351086,61.95 - 129.79,-45.939995,-0.35395637,61.95,129.79,1480291200,160.0,63.187637,1.9375151,1.327,1.01,USD,2,2452.966,84.73278,-0.882782,-0.010418423,78.18558,5.664421,0.07244842,24358172672,83.0198,0.034183107,15,America/New_York,EDT,-14400000,PNK,0,False,False,83.85,1630507163,1.2699966,84.04,84.13,83.738,2949,EISAI CO,us_market,REGULAR,0.34,,,129.79,61.95,84.73,78.19,70.54k,9.75k,286.67M,,266.58M,0.00%,0.14%,,,,,,1.5,1.82%,160.00,193.75%,2.12,77.66%,"Nov 27, 2016","Mar 28, 2021",,,"Mar 30, 2021","Jun 29, 2021",8.81%,11.71%,4.58%,8.28%,679.25B,2369.72,20.10%,484.63B,116.6B,59.85B,1.33,72.60%,213.57B,744.99,92.68B,12.40,2.02,2452.97,49.53B,8.93B,Value,112-8088,Healthcare,11237,4,1,"Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. Eisai Co., Ltd. has a research collaboration agreement with Wren Therapeutics Ltd. for the discovery of small molecules that target synuclein for the potential treatment of synucleinopathies, including Parkinson's disease and dementia with Lewy bodies; and a collaboration with BioLabs for the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups to innovate in the field of neurological diseases. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.",Tokyo,81 3 3817 3700,10,1577750400,1625097600,1,Japan,http://www.eisai.co.jp,86400,4,"4-6-10, Koishikawa",Drug Manufacturers—Specialty & Generic,Bunkyo-ku
t-1,ESALY,422759000000.0,286665984,42125000000,,-5805000000,24759000000,-3047000000,61208000000,106461000000,-4472000000,-4472000000,-1228000000,-232000000,,,,-2435000000,147610000000,152082000000,41149000000,-1333000000,,-3370000000,-3047000000,108641000000.0,77628000000.0,362067000000.0,703183000000.0,121484000000.0,1090009000000.0,44986000000.0,23909000000.0,507976000000.0,56142000000.0,171783000000.0,72593000000.0,66924000000.0,248740000000.0,256017000000.0,66923000000.0,39985000000.0,106642000000.0,160933000000.0,518344000000.0,63384000000.0,267000000.0,160310000000.0,49908000000.0,85118000000.0,94548000000.0,1000000.0,-1367000000.0,-5809000000.0,250000000.0,-2269000000.0,38256000000.0,54962000000.0,11291000000.0,51748000000.0,9468000000.0,1447000000.0,-22938000000.0,-2269000000.0,-468000000.0,-4683000000.0,-13983000000.0,25647000000.0,262327000000.0,en-US,US,EQUITY,False,Delayed Quote,1.5378985,83.738 - 84.13,82.58,0.0,0.0,0,0,finmb_685500,Other OTC,"Eisai Co., Ltd.",JPY,70543,9750,21.899998,0.35351086,61.95 - 129.79,-45.939995,-0.35395637,61.95,129.79,1480291200,160.0,63.187637,1.9375151,1.327,1.01,USD,2,2452.966,84.73278,-0.882782,-0.010418423,78.18558,5.664421,0.07244842,24358172672,83.0198,0.034183107,15,America/New_York,EDT,-14400000,PNK,0,False,False,83.85,1630507163,1.2699966,84.04,84.13,83.738,2949,EISAI CO,us_market,REGULAR,0.34,,,129.79,61.95,84.73,78.19,70.54k,9.75k,286.67M,,266.58M,0.00%,0.14%,,,,,,1.5,1.82%,160.00,193.75%,2.12,77.66%,"Nov 27, 2016","Mar 28, 2021",,,"Mar 30, 2021","Jun 29, 2021",8.81%,11.71%,4.58%,8.28%,679.25B,2369.72,20.10%,484.63B,116.6B,59.85B,1.33,72.60%,213.57B,744.99,92.68B,12.40,2.02,2452.97,49.53B,8.93B,Value,112-8088,Healthcare,11237,4,1,"Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. Eisai Co., Ltd. has a research collaboration agreement with Wren Therapeutics Ltd. for the discovery of small molecules that target synuclein for the potential treatment of synucleinopathies, including Parkinson's disease and dementia with Lewy bodies; and a collaboration with BioLabs for the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups to innovate in the field of neurological diseases. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.",Tokyo,81 3 3817 3700,10,1577750400,1625097600,1,Japan,http://www.eisai.co.jp,86400,4,"4-6-10, Koishikawa",Drug Manufacturers—Specialty & Generic,Bunkyo-ku
t-2,ESALY,404063000000.0,286665984,40643000000,,23924000000,25019000000,19370000000,77462000000,140839000000,23612000000,23612000000,-878000000,-301000000,,,,4194000000,181288000000,157676000000,40449000000,312000000,,19730000000,19370000000,107499000000.0,77631000000.0,331357000000.0,672178000000.0,121240000000.0,1028554000000.0,44986000000.0,20257000000.0,505639000000.0,50043000000.0,160616000000.0,43922000000.0,65192000000.0,193779000000.0,191430000000.0,65192000000.0,,78112000000.0,143481000000.0,495618000000.0,56148000000.0,656000000.0,201980000000.0,89884000000.0,78946000000.0,70190000000.0,123000000.0,0.0,-13652000000.0,250000000.0,-25387000000.0,-23161000000.0,-34239000000.0,1344000000.0,3455000000.0,9168000000.0,640000000.0,-22935000000.0,-2452000000.0,-6476000000.0,-1640000000.0,-13983000000.0,25647000000.0,304188000000.0,en-US,US,EQUITY,False,Delayed Quote,1.5378985,83.738 - 84.13,82.58,0.0,0.0,0,0,finmb_685500,Other OTC,"Eisai Co., Ltd.",JPY,70543,9750,21.899998,0.35351086,61.95 - 129.79,-45.939995,-0.35395637,61.95,129.79,1480291200,160.0,63.187637,1.9375151,1.327,1.01,USD,2,2452.966,84.73278,-0.882782,-0.010418423,78.18558,5.664421,0.07244842,24358172672,83.0198,0.034183107,15,America/New_York,EDT,-14400000,PNK,0,False,False,83.85,1630507163,1.2699966,84.04,84.13,83.738,2949,EISAI CO,us_market,REGULAR,0.34,,,129.79,61.95,84.73,78.19,70.54k,9.75k,286.67M,,266.58M,0.00%,0.14%,,,,,,1.5,1.82%,160.00,193.75%,2.12,77.66%,"Nov 27, 2016","Mar 28, 2021",,,"Mar 30, 2021","Jun 29, 2021",8.81%,11.71%,4.58%,8.28%,679.25B,2369.72,20.10%,484.63B,116.6B,59.85B,1.33,72.60%,213.57B,744.99,92.68B,12.40,2.02,2452.97,49.53B,8.93B,Value,112-8088,Healthcare,11237,4,1,"Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. Eisai Co., Ltd. has a research collaboration agreement with Wren Therapeutics Ltd. for the discovery of small molecules that target synuclein for the potential treatment of synucleinopathies, including Parkinson's disease and dementia with Lewy bodies; and a collaboration with BioLabs for the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups to innovate in the field of neurological diseases. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.",Tokyo,81 3 3817 3700,10,1577750400,1625097600,1,Japan,http://www.eisai.co.jp,86400,4,"4-6-10, Koishikawa",Drug Manufacturers—Specialty & Generic,Bunkyo-ku
t-3,ESALY,404309000000.0,286665984,37001000000,,1984000000,24623000000,1372000000,68975000000,110032000000,1959000000,1959000000,2097000000,-305000000,,,,613000000,151461000000,149502000000,41429000000,25000000,,1371000000,1372000000,109812000000.0,77660000000.0,343793000000.0,678204000000.0,125332000000.0,1046620000000.0,44986000000.0,17597000000.0,509578000000.0,50686000000.0,164083000000.0,45980000000.0,67982000000.0,228018000000.0,203232000000.0,67982000000.0,,80175000000.0,143104000000.0,504519000000.0,57120000000.0,947000000.0,183027000000.0,89875000000.0,74930000000.0,77900000000.0,-1000000.0,0.0,-4915000000.0,-82000000.0,-2861000000.0,-2241000000.0,1709000000.0,886000000.0,8601000000.0,8982000000.0,-315000000.0,-22935000000.0,-2779000000.0,-124000000.0,-3984000000.0,-13983000000.0,25647000000.0,301287000000.0,en-US,US,EQUITY,False,Delayed Quote,1.5378985,83.738 - 84.13,82.58,0.0,0.0,0,0,finmb_685500,Other OTC,"Eisai Co., Ltd.",JPY,70543,9750,21.899998,0.35351086,61.95 - 129.79,-45.939995,-0.35395637,61.95,129.79,1480291200,160.0,63.187637,1.9375151,1.327,1.01,USD,2,2452.966,84.73278,-0.882782,-0.010418423,78.18558,5.664421,0.07244842,24358172672,83.0198,0.034183107,15,America/New_York,EDT,-14400000,PNK,0,False,False,83.85,1630507163,1.2699966,84.04,84.13,83.738,2949,EISAI CO,us_market,REGULAR,0.34,,,129.79,61.95,84.73,78.19,70.54k,9.75k,286.67M,,266.58M,0.00%,0.14%,,,,,,1.5,1.82%,160.00,193.75%,2.12,77.66%,"Nov 27, 2016","Mar 28, 2021",,,"Mar 30, 2021","Jun 29, 2021",8.81%,11.71%,4.58%,8.28%,679.25B,2369.72,20.10%,484.63B,116.6B,59.85B,1.33,72.60%,213.57B,744.99,92.68B,12.40,2.02,2452.97,49.53B,8.93B,Value,112-8088,Healthcare,11237,4,1,"Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. Eisai Co., Ltd. has a research collaboration agreement with Wren Therapeutics Ltd. for the discovery of small molecules that target synuclein for the potential treatment of synucleinopathies, including Parkinson's disease and dementia with Lewy bodies; and a collaboration with BioLabs for the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups to innovate in the field of neurological diseases. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.",Tokyo,81 3 3817 3700,10,1577750400,1625097600,1,Japan,http://www.eisai.co.jp,86400,4,"4-6-10, Koishikawa",Drug Manufacturers—Specialty & Generic,Bunkyo-ku
